• Royalty Pharma reported its Q4 and full year 2024 financial results on February 11, 2025.
• Portfolio Receipts were $742 million in Q4 2024 and $2,801 million for the full year.
• Royalty Receipts grew by 12% in Q4 2024 and 13% for the full year, reaching $729 million and $2,771 million, respectively.
• Net cash provided by operating activities was $743 million in Q4 2024 and $2,769 million for the full year.
• The company deployed $2.8 billion of capital in 2024, adding royalties on eight new therapies.
• Royalty Pharma expects 2025 Portfolio Receipts to be between $2,900 million and $3,050 million, representing growth of 4% to 9%.
• In January 2025, Royalty Pharma announced the acquisition of its external manager and a new $3 billion share repurchase program.
• The acquisition of the external manager is expected to generate cash savings of greater than $100 million in 2026, rising to greater than $175 million in 2030, with cumulative savings of greater than $1.6 billion over ten years.

Score: 7

Explanation: The document presents a mixed sentiment. While Royalty Receipts show strong growth and strategic initiatives like the acquisition of the external manager and share repurchase program are positive, the decrease in Portfolio Receipts and other financial metrics for the full year tempers the overall outlook.

• Royalty Receipts grew 12% to $729 million in Q4 2024 and 13% to $2,771 million for the full year, driven by strong performance from Evrysdi, the CF franchise, Trelegy, Tremfya and new royalty acquisitions.
• Portfolio Receipts increased 1% to $742 million in Q4 2024, but decreased 8% to $2,801 million for the full year, largely reflecting $525 million in Biohaven-related milestone payments received in 2023.
• Capital deployment reached $2.8 billion in 2024, including $925 million in synthetic royalty transactions.
• Royalty Pharma expects 2025 Portfolio Receipts to be between $2,900 million and $3,050 million, representing expected growth of 4% to 9%.
• The acquisition of the external manager is expected to result in cash savings of greater than $100 million in 2026, rising to greater than $175 million in 2030, with cumulative savings of greater than $1.6 billion over ten years.
• A new $3 billion share repurchase program was authorized in January 2025, with $2 billion intended to be repurchased in 2025.

• Royalty Receipts showed strong growth, increasing by 12% in Q4 2024 and 13% for the full year.
• The company deployed $2.8 billion in capital in 2024, expanding its portfolio with royalties on eight new therapies.
• The acquisition of the external manager is expected to generate significant cost savings, exceeding $100 million in 2026 and $175 million by 2030.
• A new $3 billion share repurchase program signals confidence in the business and attractive value in the shares.
• The sale of MorphoSys Development Funding Bonds resulted in total cash proceeds of $530 million on a $300 million investment.

• Portfolio Receipts decreased by 8% for the full year 2024, primarily due to the absence of $525 million in Biohaven-related milestone payments received in 2023.
• Net cash provided by operating activities decreased by 7% for the full year 2024.
• Adjusted EBITDA and Portfolio Cash Flow both decreased by 9% for the full year 2024.

• The forward-looking statements are subject to risks, uncertainties, and other variable circumstances that could cause actual results to differ materially.
• The company relies on third-party data, which has not been independently verified.
• The company's projections assume no additional debt financing in 2025, including no drawdown on the revolving credit facility.
• Novartis will continue to follow patients in MANIFEST-2 and evaluate the potential for additional studies to support registration of pelabresib in myelofibrosis.
• Gilead announced plans to voluntarily withdraw the U.S. accelerated approval of Trodelvy for use in pre-treated adult patients with locally advanced or metastatic urothelial cancer, following the results of the Phase 3 TROPiCS-04 trial.

Royalty Pharma expects 2025 Portfolio Receipts to be between $2,900 million and $3,050 million, representing expected growth of 4% to 9%.

• We had an incredibly successful 2024, delivering double-digit growth in Royalty Receipts, which was significantly above our initial guidance, and deploying $2.8 billion of capital on value-enhancing royalties said Pablo Legorreta, Royalty Pharmas founder and Chief Executive Officer.
• With a robust transaction pipeline and significant financial flexibility, I am confident that Royalty Pharma is well positioned to deliver attractive, compounding growth over the long term.

Royalty Pharma's business model focuses on acquiring royalty streams from biopharmaceutical products, providing a diversified revenue base and mitigating risks associated with individual drug development. The acquisition of its external manager and the share repurchase program reflect a strategic shift towards enhancing shareholder value and simplifying the corporate structure.

• Royalty Pharma's focus on royalty acquisitions distinguishes it from traditional pharmaceutical companies that rely on internal R&D or direct acquisitions of drug candidates.
• Comparable companies in the royalty space include DRI Healthcare Trust and Healthcare Royalty Partners, but Royalty Pharma is significantly larger in terms of market capitalization and portfolio size.
• The company's capital deployment strategy and focus on late-stage and commercial products align with industry trends of de-risking investments in the biopharmaceutical sector.
• The share repurchase program is a common strategy among large pharmaceutical companies to return capital to shareholders, similar to programs implemented by companies like Pfizer and Johnson & Johnson.

• Shareholders will benefit from the share repurchase program and potential cost savings from the internalization transaction.
• Employees of the external manager will transition to Royalty Pharma upon completion of the acquisition.
• The company's investments in biopharmaceutical royalties support innovation and development of new therapies, benefiting patients.
• Creditors are impacted by the company's debt management and liquidity position.

• Closing of the internalization transaction, expected in the second quarter of 2025, subject to shareholder and regulatory approvals.
• Continued execution of the $3 billion share repurchase program, with $2 billion planned for 2025.
• Monitoring of key developments related to the portfolio, including regulatory decisions and clinical trial results.
• Novartis will continue to follow patients in MANIFEST-2 and evaluate the potential for additional studies to support registration of pelabresib in myelofibrosis.

• 1996: Royalty Pharma was founded.
• September 2022: Royalty Pharma made a $300 million investment in MorphoSys Development Funding Bonds.
• March 2023: Royalty Pharma announced an original $1.0 billion share repurchase program.
• October 2023: Royalty Pharma acquired additional royalties on Evrysdi.
• June 2024: Royalty Pharma acquired additional royalties on Evrysdi and issued $1.5 billion in notes.
• December 31, 2024: End of the reporting period for Q4 and full year 2024 financial results.
• January 8, 2025: The total transaction value of approximately $1.1 billion for the acquisition of RP Management, LLC is based on the closing price of Royalty Pharma plc common stock of $26.20.
• January 10, 2025: Royalty Pharma announced the agreement to acquire its external manager, RP Management, LLC.
• January 2025: Royalty Pharma announced the sale of the MorphoSys Development Funding Bonds for $511 million in upfront cash and the Board of Directors authorized a new share repurchase program under which Royalty Pharma may repurchase up to $3.0 billion of its Class A ordinary shares.
• February 11, 2025: Royalty Pharma reported Q4 and full year 2024 financial results and provided 2025 financial outlook.
• Q2 2025: Estimated closing of the internalization transaction, subject to shareholder approval and regulatory approvals.
• July 27, 2025: FDA PDUFA goal date for Ascendis' sBLA in adult growth hormone deficiency for Skytrofa.
• September 26, 2025: FDA PDUFA date for Cytokinetics' NDA for aficamten for the treatment of Obstructive Hypertrophic Cardiomyopathy.